| Autor: |
Tatham, Kate C., Shankar-Hari, Manu, Arabi, Yaseen M. |
| Předmět: |
|
| Zdroj: |
Intensive Care Medicine; Nov2021, Vol. 47 Issue 11, p1315-1318, 4p |
| Abstrakt: |
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The trial population of REMDACTA trial appears similar to the RECOVERY Trial that showed benefit with tocilizumab, with one key difference: RECOVERY trial eligibility criteria included C-reactive protein (CRP) values > 75 mg/L as a marker of inflammation [[7]]. However, in the RECOVERY Trial that enrolled a similar target population, there was additional benefit with tocilizumab in those patients who got corticosteroids [[7]], a treatment effect that was replicated in critically ill patients [[15]] and in all illness severity states within the PMA [[5]]. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink